A global leader in influenza prevention announced that the company co-authored the first study to demonstrate the safety, immunogenicity, and efficacy profile of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine.
Maryland-based Novavax, Inc. conducted the sub-study as part of a Phase 3 clinical trial of NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate.
Flu Shots and COVID-19 Vaccine Mix Very Well
Flu Shots and COVID-19 Vaccine Mix Very Well
A global leader in influenza prevention announced that the company co-authored the first study to demonstrate the safety, immunogenicity, and efficacy profile of a COVID-19 vaccine when co-administered with a seasonal influenza vaccine.
Maryland-based Novavax, Inc. conducted the sub-study as part of a Phase 3 clinical trial of NVX-CoV2373, its recombinant protein COVID-19 vaccine candidate.
Third COVID-19 Vaccine Dose Tried in Organ Transplant Recipients
Six patients with low-positive antibody levels following standard vaccination achieved high-positive levels after dose 3
AMA: 96 Percent of Physicians Fully Vaccinated Against COVID-19
No significant differences seen in physician vaccination rates across demographic groups, including region, gender, age
SARS-CoV-2 Infection Cuts Risk for Reinfection for Up to 10 Months
Risk for PCR-positive infection higher for residents, staff of long-term care facilities who were antibody-negative at baseline
SARS-CoV-2 Antibodies Identified Before Cases Recognized in U.S.
Nine seropositive blood specimens ID’d from Jan. 2 to March 19, 2020; seven prior to first confirmed cases in five states
Stressors of Integrating Work, Life Higher for Female Faculty
Since COVID-19, faculty more likely to consider leaving, reducing employment, especially female faculty members
California Lifts Most COVID-19 Restrictions
However, reopening does not mean the pandemic is over, and some public health measures will still be in place for ‘mega events’